The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA; Breast Cancer Research And Treatment, 2009, vol. 116, issue 2, p 303, ISSN 15737217. ISBN 15737217.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef